IQVIA (IMS

Biosimilars are very far from reaching their full potential, in terms of market share and the savings to the health care system that they’re bringing.

By the numbers: The 7 biosimilars that are on the market are creating $253.8 million in savings, the paper estimates.

• But that’s with market shares that are almost all in the single digits, meaning they’re barely making a dent against the innovator biologics that they’re competing with.

• The one exception is Zarxio — a competitor to Neupogen, a drug administered to cancer patients — which makes up about 55% of the market.

• A dozen more biosimilars have been approved in the U.S. but are not yet on the market. In total, biosimilars have been approved for 9 drug classes.

IQVIA (IMS) is rethinking how to provide consumers with the complete understanding, tools, evidence and communications to help you realize that potential.

Innovating new study options. Applying advances in machine learning. Collaborating with providers and payers. Scaling evidence investments. We are committed to bringing you value across the clinical and commercial lifecycle through a deeper portfolio of real-world solutions.